Current Report ESPI 20/2025

The Management Board of Ryvu Therapeutics S.A., with its registered office in Kraków (the “Company”), announces that on June 18, 2025, it received a notification from the Company’s shareholder, Mr. Tadeusz Wesołowski, submitted pursuant to Article 69(1)(1) and Article 69a(1)(3) of the Act of July 29, 2005 on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organized Trading, and Public Companies.

According to the content of the notification, as a result of the indirect acquisition of the Company’s shares by Mr. Tadeusz Wesołowski in the transactions disclosed by the Company in current reports No. 16/2025 of June 9, 2025, No. 18/2025 of June 12, 2025, and No. 19/2025 of June 18, 2025, the total share of Mr. Tadeusz Wesołowski and affiliated entities in the overall number of votes at the Company’s General Meeting amounts to 5.05% and has not changed.

The full content of the notification is attached to this report.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

 

Legal basis: Article 70 point 1 of the Public Offering Act

Representatives of the Issuer:

• Paweł Przewięźlikowski – President of the Management Board
• Kamil Sitarz – Member of the Management Board